EMEA-000170-PIP03-13-M04
Key facts
| Invented name |
Revolade
|
| Active substance |
Eltrombopag
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0516/2020
|
| PIP number |
EMEA-000170-PIP03-13-M04
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of aplastic anaemia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Limited
Tel. +41 6132 41111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|